医疗器械公司TransMedics Group Inc.(TMDX.US)盘中大跌超过32%,引起市场高度关注。此前该公司发布的2024年第三季度财报数据远逊市场预期,令投资者对其未来增长前景产生质疑。
根据财报显示,TransMedics Group第三季度营收为1.088亿美元,远低于华尔街分析师平均预期的1.15亿美元。净利润仅为每股12美分,同样未能达到预期的每股29美分。虽然公司维持了全年营收在4.25亿至4.45亿美元的指引,但投资者显然对其业绩增长表示失望。
TransMedics Group是一家专注于为终末期器官衰竭患者提供移植治疗的医疗技术公司。本季度财报数据暴露出公司在某些领域可能面临增长瓶颈,无法继续保持之前的高速增长势头。这引发了投资者对公司前景的担忧,导致其股价在盘后出现重挫,跌幅高达28.87%,报收于90.20美元。分析师纷纷下调了对公司的盈利预测和目标价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.